GH RESEARCH
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
GH RESEARCH
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2018-01-01
Address:
Dublin, Dublin, Ireland
Country:
Ireland
Website Url:
http://www.ghres.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
125 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Office 365 Mail IPv6
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Employees Featured
Founder
Stock Details
Investors List
Logos Capital
Logos Capital investment in Series B - GH Research
Surveyor Capital
Surveyor Capital investment in Series B - GH Research
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series B - GH Research
Verition Fund Management
Verition Fund Management investment in Series B - GH Research
Boxer Capital
Boxer Capital investment in Series B - GH Research
RA Capital Management
RA Capital Management investment in Series B - GH Research
RTW Investments LLC
RTW Investments LLC investment in Series B - GH Research
Cormorant Asset Management
Cormorant Asset Management investment in Series B - GH Research
Acuta Capital Partners
Acuta Capital Partners investment in Series B - GH Research
BVF Partners
BVF Partners investment in Series B - GH Research
Official Site Inspections
http://www.ghres.com Semrush global rank: 3.9 M Semrush visits lastest month: 3.26 K
- Host name: cloudhost-743762.nl-west-1.nxcli.net
- IP address: 185.145.13.140
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "GH Research"
About Us | GH Research
GH Research was founded in 2018, and since then, two of our novel and proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidates have entered clinical …See details»
GH Research - Crunchbase Company Profile & Funding
Contact Email [email protected] GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH …See details»
Executive Team | GH Research
Our executive team brings together a wealth of diverse experiences and a proven track record of success in the pharmaceutical industry. Guided by their entrepreneurial spirit, our team is …See details»
Investor Relations | GH Research
Nov 14, 2024 We are a clinical-stage pharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Our initial focus is on developing our novel …See details»
GH Research plc - LinkedIn
GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.See details»
Investor FAQs - GH Research
For all other investor inquiries, please contact [email protected]. Does GH Research have a direct stock purchase plan? We do not currently have a direct stock purchase plan. Our …See details»
Corporate Presentation - investor.ghres.com
2024© GH Research PLC First Line MDD Second Line MDD Treatment-Resistant Depression (TRD) Patients cycle through ineffective therapies for TRD •Diagnosed: ~48M •Treated …See details»
GH Research - VentureRadar
"GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Our initial focus is on developing our novel …See details»
Board of Directors | GH Research
Our board of directors bring a wealth of experience and an impressive track record of success in biopharmaceutical entrepreneurship and investment.See details»
GH Research Provides Business Updates and Highlights Key …
Jan 9, 2023 Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023Development of proprietary aerosol delivery device …See details»
GH Research Provides Business Updates and Highlights Key …
Jan 25, 2023 GH Research PLC’s annual report on Form 20-F filed with the U.S. Securities and Exchange Commission for the year ended December 31, 2021 is available at www.ghres.com …See details»
GH Research Provides Business Updates and Highlights Key
Jan 9, 2023 GH Research PLC's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission for the year ended December 31, 2021 is available at www.ghres.com …See details»
Legal | GH Research
The Group may not retaliate against you for any of these activities, and nothing in this Policy or otherwise requires you to waive any monetary award or other payment that you might become …See details»
GH Research Provides Updates and Guidance on its Clinical …
Sep 29, 2023 GH Research PLC's annual report on Form 20-F/A filed with the U.S. Securities and Exchange Commission for the year ended December 31, 2022 is available at …See details»
Corporate Presentation - GH Research
•Mebufotenin (5-Methoxy-N,N-Dimethyltryptamine, 5-MeO-DMT) • Naturally-occurring psychoactive substance from tryptamine class • Highly potent agonist on 5-HT1A and 5-HT2A …See details»
GH Research PLC (GHRS) Stock Price, Quote & News - Stock Analysis
Website https://www.ghres.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 3 analysts, the average rating for GHRS stock is …See details»
Release Details - investor.ghres.com
Sep 3, 2024 [email protected]. GH RESEARCH PLC Condensed Consolidated Interim Statement of Comprehensive Income (Unaudited) (in thousands, except share and per share …See details»
GH Research (GHRS) Stock Price, News & Analysis - MarketBeat
6 days ago www.ghres.com. Phone 212-450-4000. Fax N/A. Employees 10. Year Founded N/A. Price Target and Rating. Average Stock Price Target $35.67. High Stock Price Target $40.00. …See details»
Working at GH Research | GH Research
GH Research was established on the basis of three core principles: Deep thinking – understanding challenges at a fundamental level, questioning the status quo and developing …See details»